BD ranks among top 25 U.S. companies in newsweek`s 2010 green rankings; receives EPA green power leadership award
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has ranked among the top 25 companies in Newsweek's second annual 'Green Rankings' of the 500 largest U.S. corporations based on environmental performance, policies and reputation. BD ranked 24th overall and second in the Healthcare sector.
BD has also received a 2010 Green Power Leadership Award from the U.S. Environmental Protection Agency (EPA). BD was one of only ten organizations nationwide to receive a Leadership Award in the Green Power Purchase Award category. The annual awards recognize EPA Green Power Partners for their commitment and contribution to helping advance the development of the nation's voluntary green power market. According to the EPA, BD's current green power purchase of nearly 201 million kWh is equivalent to avoiding the carbon dioxide (CO2) emissions of nearly 28,000 passenger vehicles per year, or is the equivalent amount of electricity needed to power more than 17,000 average American homes annually.
'As part of BD's long-term vision for sustainability, we seek to ensure that our business decisions are consistent with our desire to improve the environmental, health and social well being of our associates, the people we serve and the communities where we operate,' said Edward J. Ludwig, BD Chairman and Chief Executive Officer. 'While we are reducing the environmental footprint of our operations, we are also incorporating sustainability into our product development and research and development processes.'
'Purchasing green power helps our organization become more sustainable, while also sending a message to others across the U.S. that supporting clean sources of electricity is a sound business decision and an important choice to fight climate change,' said Glenn Barbi, BD Vice President, Global Sustainability.
Additionally, BD has been selected as a component of the Dow Jones Sustainability World Index (DJSI World) and the DJSI North America Index for the fifth and sixth consecutive years, respectively. Dow Jones Sustainability Index assessments examine corporate economic, environmental and social performance, with a strong focus on long-term shareholder value. Inclusion in the DJSI World Index puts BD in the top 10 percent of companies in the healthcare sector assessed for sustainability leadership.
To produce the 2010 Green Rankings, Newsweek collaborated with MSCI ESG Research; Trucost; CorporateRegister.com; and ASAP Media. To view the full list, please visit www.newsweek.com/green.
The EPA Green Power Partnership is a voluntary program that encourages organizations to buy green power as a way to reduce the environmental impacts associated with purchased electricity use. The Partnership currently has nearly 1,300 Partner organizations voluntarily purchasing billions of kilowatt-hours of green power annually. For additional information, please visit http://www.epa.gov/greenpower.
Launched in 1999, the Dow Jones Sustainability Indexes are the first global indexes tracking the financial performance of the leading sustainability-driven companies worldwide. To learn more, please visit www.sustainability-index.com.
To learn more about BD's commitment to environmental stewardship, and to access BD's 2009 Sustainability Report, please visit http://www.bd.com/sustainability.
About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
Related news
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease. The company will intensify investments in the development of its genomic-aware data lake to...
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol “DXR” after the transfer. The Company’s common stock will continue to trade on the NYSE American until the...
-
The Indoor Microbiome and Its Impact on Indoor Environmental Quality
Last year, the U.S. Environmental Protection Agency (EPA) announced the release of a new webpage to provide information about the indoor microbiome. All of the living microorganisms inside of an indoor environment, and their by-products, are collectively known as the indoor microbiome. The indoor microbiome that surrounds each of us is diverse and dynamic, made up of bacteria, viruses, fungi and other single-celled organisms. These microorganisms may be growing or inactive, and may be present in different life...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress with BVA-100® next generation development. The presentation will be available on-demand beginning at 7:00 a.m. ET...
-
Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic. Dr. Jan Bakker, MD,...
Customer comments
No comments were found for BD ranks among top 25 U.S. companies in newsweek`s 2010 green rankings; receives EPA green power leadership award. Be the first to comment!